Navigation Links
The Continued Uptake of Key Agents Such as Januvia, Bydureon and Byetta Will Drive The Type 2 Diabetes Drug Market to Nearly Double From $19 Billion in 2009 to $36 Billion in 2019
Date:9/21/2010

BURLINGTON, Mass., Sept. 21 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the continued uptake of key agents such as Merck's Januvia, Eli Lilly/Amylin/Alkermes' Bydureon and Amylin/Eli Lilly's Byetta will drive the type 2 diabetes drug market to nearly double from $19 billion in 2009 to $36 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Type 2 Diabetes reveal that agents from the incretin mimetics drug class—dipeptidyl peptidase-IV (DPP-IV) inhibitors and glucagon-like peptide-1 (GLP-1) analogues—are the most promising drug classes because they improve upon key areas of safety and efficacy. DPP-IV inhibitors such as Januvia have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues such as Bydureon and Byetta combine superior glucose-lowering and weight-loss capabilities and are particularly useful for the significant proportion of type 2 diabetics who are obese. Among all drug classes, DPP-IV inhibitors and GLP-1 analogues will experience the largest upturn in market share, increasing from 12 percent in 2009 to 30 percent in 2019.

"Januvia dominates the DPP-IV inhibitor class and will consolidate its leading position while other DPP-IV inhibitors will struggle, owing to their lack of clinical advantages over Januvia," said Decision Resources Analyst Yannick Maneuf, Ph.D. "GLP-1 analogues have a strong efficacy profile, they elicit weight loss and also have limited safety liabilities and—despite requiring an injection—GLP-1 analogues enjoy great popularity among thought leaders, who see improved glycemia and weight loss in obese type 2 diabetics as landmark progress."

Bydureon, a once-weekly therapy, will earn the most sales in the GLP-1 analogue class, based on its convenience and efficacy. Bydureon and Novo Nordisk's once-daily Victoza will also benefit as a result of the failure of Roche/Ipsen/Teijin/Chugai's taspoglutide, which was the second-most-advanced contender among the long-acting GLP-1 analogues.

The Pharmacor 2010 findings also reveal that although an advisory committee of the U.S. Food and Drug Administration recently agreed to keep GlaxoSmithKline's PPAR-gamma agonist Avandia on the market, the drug will continue to lose sales through 2019 to its main competitor from the same drug class, Takeda's Actos.

About Pharmacor 2010The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.For more information, contact:Decision Resources, Inc.Christopher Comfort781-993-2597 ccomfort@dresources.com
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. K-V Pharmaceutical Company Receives Notification From New York Stock Exchange of Compliance With Quantitative Continued Listing Standards
2. Interventional Spine®, Inc. Announces Continued Success With Its Unique PERPOS® Percutaneous Cervical System
3. K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards
4. Caraco Pharmaceutical Laboratories, Ltd. Receives Notice Regarding NYSE Amex Continued Listing Standards
5. Department of Defense Funding Shows Continued and Bi-Partisan Support for STB® Lifesaving Technologies Products to Stop Blood Loss
6. Extension Study With FIRMAGON® (degarelix) Showed Continued Benefits for Prostate Cancer Patients Beyond One Year
7. Abbott Annual Meeting Highlights Continued Strong Performance in 2009; Sustained Growth in 2010
8. Philips Introduces Breakthrough Medical Alert Service That Helps Enable Continued Independence for Seniors by Improving Access to Help in the Event of a Fall
9. NYSE Amex Provides Interleukin Genetics, Inc. Extension To Meet Continued Listing Standards
10. Benefits of CyberKnife Radiosurgery for Lung Cancer Drive Continued Adoption
11. Pharmasset Announces the Continued Enrollment of the Phase 2b Clinical Trial of RG7128 for the Treatment of Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/5/2017)... -- Sapheneia and Scannerside received FDA 510(k) clearance to ... third-party Vendor neutral CT product that makes it affordable ... current MITA standards. ... specifically designed to provide CT operators, prior to a ... a predefined threshold. Scannerside Dose Check is intended to ...
(Date:9/1/2017)... 1, 2017 Michael Penna , President ... highlights opportunities for growth in his response to the ... Equity is seeking a buyer for eMDs. Penna,s company, ... healthcare solutions Value Added Reseller and national leader in ... "As the healthcare market continues to dictate ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... ... PITTSBURGH...An inventor, from Richmond Hill, Ga., thought there needed to be a quick ... invented the COMPLETE PATIENT CHART. , The COMPLETE PATIENT CHART provides a more effective ... alternative to paper charts and clipboards. As a result, it increases efficiency and it ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... science and technology-enabled services supporting clinical research, today announces that 30 of ... aspects of the drug development lifecycle at upcoming industry conferences and webinars. ...
(Date:9/25/2017)... ... September 25, 2017 , ... Earlypicker is expanding its offerings to include ... the hottest Korean cosmetics and fashion trends sweeping the nation. The decision to expand ... for the great offerings that allow Koreans everywhere to look their best every single ...
(Date:9/25/2017)... ... September 25, 2017 , ... “The Majestic Unicorn”: a poignant ... “The Majestic Unicorn” is the creation of published author, Dayna Chantel, an artist and ... far and wide to march aboard the cypress ark-vessel. Male and female, no matter ...
(Date:9/25/2017)... ... ... kill Ash trees in as little as 1-3 years. The signs of this ... Nagy, ISA Certified Arborist at Giroud Tree and Lawn, shows a street in Northeast Philadelphia ... decline from Emerald Ash Borers, two Ash trees continue to thrive. , "The ...
Breaking Medicine News(10 mins):